| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SMND-309 targets multiple signaling pathways involved in cell survival and neuroprotection. It promotes neuron survival through the activation of the PI3K/Akt/CREB-signaling pathway. SMND-309 also activates the erythropoietin receptor/STAT3/VEGF pathways and the JAK2/STAT3 signaling pathway, which plays a crucial role in cellular survival and angiogenesis.
|
|---|---|
| ln Vitro |
SMND-309 promotes neuron survival in vitro and exhibits neuroprotective effects in cultured rat cortical neurons. It attenuates apoptosis and ameliorates mitochondrial energy metabolism in rat cortical neurons, increasing cell survival rate. The compound has shown protective effects against rat cortical neuron damage with defined IC50 values.
|
| ln Vivo |
Male Sprague-Dawley rats treated with SMND-309 (2.5–10 mg/kg; oral gavage; once daily; for four weeks) showed better liver function, decreased levels of type III procollagen, laminin, and hyaluronic acid in the blood, and increased hydroxyproline content in the liver tissue. Additionally, SMND-309 recovers diminished glutathione peroxidase and superoxide dismutase capabilities as well as lowers high malondialdehyde levels. SMND-309 treatment decreased liver fibrosis and liver damage. Treatment with SMND-309 has the ability to significantly reduce the expression of connective tissue growth factor (CTGF) in the liver and serum [1].
SMND-309 exhibits neuroprotective effects in vivo in rats with neuronal damage and permanent cerebral artery occlusion. It decreases liver fibrosis and liver damage, significantly reducing the expression of connective tissue growth factor (CTGF) in the liver and serum. SMND-309 has therapeutic effects on experimental liver fibrosis, ameliorating liver function and reducing fibrosis. |
| Enzyme Assay |
SMND-309's neuroprotective activity can be assessed using in vitro assays with primary rat cortical neurons. Neurons are exposed to neurotoxic insults (e.g., oxygen-glucose deprivation or glutamate excitotoxicity) in the presence of varying concentrations of SMND-309. Cell survival is measured using MTT or LDH release assays. Activation of PI3K/Akt/CREB and JAK2/STAT3 pathways is confirmed by Western blot analysis of phosphorylated signaling proteins.
|
| Cell Assay |
The cellular activity of SMND-309 is evaluated in primary rat cortical neuron cultures or neuronal cell lines. Cells are treated with increasing concentrations of SMND-309, and cell viability is assessed using MTT or calcein-AM staining. Apoptosis is measured by caspase-3 activity or TUNEL staining. Mitochondrial function is assessed by measuring ATP levels or mitochondrial membrane potential. Signaling pathway activation is confirmed by Western blot analysis.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (180-200 g) carbon tetrachloride [1]
Doses: 2.5 mg/kg, 5 mg/kg and 10 mg/kg Route of Administration: po (oral gavage); one time/day; 4 Weekly Experimental Results: The anti-fibrosis mechanism may be related to its inhibition of CTGF expression, removal of lipid peroxidation products, and increase in endogenous antioxidant enzyme activity. In rat models of cerebral ischemia or permanent cerebral artery occlusion, SMND-309 is administered via intravenous or intraperitoneal routes. Neurological deficits are scored, and infarct volume is measured by TTC staining. In models of liver fibrosis, SMND-309 is administered orally or intraperitoneally, and liver function markers (ALT, AST), fibrosis markers (CTGF, collagen), and histological analysis are performed to assess therapeutic effects. |
| ADME/Pharmacokinetics |
SMND-309 has a molecular formula of C18H14O8 and a molecular weight of 358.30 g/mol. It is a synthetic derivative of salvianolic acid B. Specific pharmacokinetic parameters such as half-life, bioavailability, and plasma protein binding are not extensively detailed in standard reference sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SMND-309 is not extensively documented. As a derivative of a natural product from Salvia miltiorrhiza, it is expected to have a favorable safety profile. Specific LD50 values and organ-specific toxicity data are not readily available in the public domain.
|
| References |
|
| Additional Infomation |
SMND-309 (CAS# 1065559-56-9) is also known as a novel derivative of salvianolic acid B. It promotes neuron survival through activation of PI3K/Akt/CREB and JAK2/STAT3 signaling pathways. SMND-309 has therapeutic potential for neurological disorders, cerebral ischemia, and liver fibrosis.
|
| Molecular Formula |
C18H14O8
|
|---|---|
| Molecular Weight |
358.302
|
| Exact Mass |
358.069
|
| CAS # |
1065559-56-9
|
| PubChem CID |
45138954
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.232
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
584
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1/C=C(\C2=C(C=CC(=C2O)O)/C=C/C(=O)O)/C(=O)O)O)O
|
| InChi Key |
OAHRXWZJURTMHG-ACIWFXKJSA-N
|
| InChi Code |
InChI=1S/C18H14O8/c19-12-4-1-9(8-14(12)21)7-11(18(25)26)16-10(3-6-15(22)23)2-5-13(20)17(16)24/h1-8,19-21,24H,(H,22,23)(H,25,26)/b6-3+,11-7+
|
| Chemical Name |
(E)-2-[6-[(E)-2-carboxyethenyl]-2,3-dihydroxyphenyl]-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
|
| Synonyms |
SMND309; SMND 309; SMND-309
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 3.7 mg/mL (~10.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7910 mL | 13.9548 mL | 27.9096 mL | |
| 5 mM | 0.5582 mL | 2.7910 mL | 5.5819 mL | |
| 10 mM | 0.2791 mL | 1.3955 mL | 2.7910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
